Adagio has raised money in a GV-led series B round that will support the entry of its covid-19 drug candidate into clinical trials early next year.

Julius-Maximilians-University of Würzburg's cancer immunotherapy developer Catalym plans to move its lead asset into the clinic next month.

Legend Capital was among the participants as Rec-Biotechnology raised series B funding that will be used for clinical trials of its vaccine candidates.

Salesforce Ventures returned to help the virtual event software provider hike its valuation to $2.15bn in its third round this year.

Novartis Venture Fund took part in a series B round closed as Catalym prepares to move its lead cancer immunotherapy asset into the clinic next month.

Subsidiaries of Intel, Qualcomm, Samsung, Verizon and Sonae all contributed to help push the mobile optimisation software provider's overall funding above $56m.

Grab led a series B round for the digital wallet provider that also featured Telkomsel and corporate venturing units BRI Ventures and Mandiri Capital.

Founding investors G7, GLP and Nio Capital returned to reinvest in the autonomous trucking system developer, in a round led by battery maker CATL.

Castor Ventures Fund took part in a round that will be used to strengthen Ayar's optical interconnector technology, which is based on MIT research.

Global Foundries, Intel, Applied Materials and Lockheed Martin all helped push the optical transceiver technology developer's total funding past $60m.